These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Regression of white matter MRI abnormalities in nonvasculitic autoimmune inflammatory meningoencephalitis following intravenous immunoglobulin. Imperiale D; Guastamacchia G; Duca S; Appendino L; Marietti G; Romito A; Atzori C; Buffa C Eur Neurol; 2007; 57(4):244-5. PubMed ID: 17389804 [No Abstract] [Full Text] [Related]
4. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia. Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345 [TBL] [Abstract][Full Text] [Related]
5. A review of the current use of rituximab in autoimmune diseases. Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786 [TBL] [Abstract][Full Text] [Related]
7. Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. Lyons MK; Caselli RJ; Parisi JE J Neurosurg; 2008 May; 108(5):1024-7. PubMed ID: 18447724 [TBL] [Abstract][Full Text] [Related]
8. [Safety of rituximab in patients with rheumatoid arthritis]. Morović-Vergles J Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022 [TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X; Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726 [TBL] [Abstract][Full Text] [Related]
10. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699 [TBL] [Abstract][Full Text] [Related]
11. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature. Guidelli GM; Fioravanti A; Rubegni P; Feci L Rheumatol Int; 2013 Nov; 33(11):2927-30. PubMed ID: 23135613 [TBL] [Abstract][Full Text] [Related]
12. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Salman-Monte TC; Lisbona MP; García-Retortillo M; Maymó J Reumatol Clin; 2014; 10(3):196-7. PubMed ID: 24054835 [No Abstract] [Full Text] [Related]
13. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117 [TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318 [TBL] [Abstract][Full Text] [Related]
15. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Guzman Moreno R Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204 [TBL] [Abstract][Full Text] [Related]
16. B-cell therapies in established rheumatoid arthritis. Leandro MJ; Becerra-Fernandez E Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923 [TBL] [Abstract][Full Text] [Related]
17. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X; Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531 [TBL] [Abstract][Full Text] [Related]
18. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216 [TBL] [Abstract][Full Text] [Related]
19. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis]. Roccatello D; Vangelista A; Pani A G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261 [TBL] [Abstract][Full Text] [Related]
20. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]